research use only
Cat.No.S5623
| Related Targets | CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel GluR |
|---|---|
| Other ATPase Inhibitors | (-)-Blebbistatin Thapsigargin Brefeldin A (BFA chemical) CB-5083 Golgicide A Sodium orthovanadate Bufalin CDN1163 Ginsenoside Rb1 Oligomycin |
|
In vitro |
DMSO
: 33 mg/mL
(59.4 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 555.50 | Formula | C32H31BrN2O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 843663-66-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | TMC-207, R207910 | SMILES | CN(C)CCC(C1=CC=CC2=CC=CC=C21)(C(C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
mycobacterial ATP synthase
|
|---|---|
| In vitro |
Bedaquiline targets against Mycobacterial ATP synthase complex. This compound has anti-cancer activity, directed against Cancer Stem-like Cells (CSCs). Its treatment of MCF7 breast cancer cells inhibits mitochondrial oxygen-consumption, as well as glycolysis, but induces oxidative stress. It reduces mitochondrial membrane potential, with a significant rise in ROS levels. It specifically inhibits mitochondrial respiration in cancer cells, while enhancing mitochondrial function in normal cells. This chemical dramatically inhibits oxygen consumption and ATP production in the low micromolar range. In addition, its treatment also reduced aerobic glycolysis.
|
| In vivo |
Bedaquiline follows triphasic elimination and characterized by an outstandingly long terminal half-life, around 173 h in humans.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2026-06-30)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07675954 | NOT_YET_RECRUITING | Rifampicin-Resistant Tuberculosis |
Seoul National University Hospital |
2026-10-01 | PHASE3 |
| NCT06441006 | RECRUITING | Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR |
University of California, San Francisco |
2025-10-03 | PHASE2; PHASE3 |
| NCT07485010 | NOT_YET_RECRUITING | Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease |
The University of Queensland |
2027-04 | PHASE2 |
| NCT07486024 | NOT_YET_RECRUITING | MDR-TB; Tuberculosis Multi Drug Resistant Active; Antibiotic Resistance; Mycobacterium Tuberculosis |
Assistance Publique - Hôpitaux de Paris |
2026-04 | PHASE3 |
| NCT07076225 | NOT_YET_RECRUITING | Pulmonary Tuberculosis |
Shenzhen Third People's Hospital |
2025-07-25 | PHASE3 |
| NCT04310930 | RECRUITING | Pulmonary Disease Due to Mycobacteria (Diagnosis) |
The University of Queensland |
2020-03-02 | PHASE2; PHASE3 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.